Abstract LBA75
Background
One-third of patients with oesophageal cancer has a pathologically complete response after neoadjuvant chemoradiotherapy (nCRT) plus oesophagectomy. Active surveillance may be an alternative for patients with clinically complete response (CCR).
Methods
A noninferiority stepped-wedge cluster randomised trial was performed. Patients with CCR (i.e. no residual disease 6 and 12 weeks after nCRT) underwent active surveillance (surgery only when locoregional regrowth was detected) or standard surgery. Primary endpoint was overall survival (OS) from day of CCR. Noninferiority was defined as Hazard Ratio (HR) <1.77 for mortality in active surveillance after two years. Secondary endpoints were operative outcomes, disease-free survival (DFS), distant dissemination rate and quality of life (HRQOL, EORTC QLQ-C30).
Results
Some 198 patients underwent active surveillance and 111 patients underwent standard surgery. Median follow-up was 34 months in active surveillance and 50 months in standard surgery. OS in active surveillance was noninferior to standard surgery (HR 0.88, 95% upper boundary 1.40, p = 0.007). During active surveillance, 69 patients (35%) maintained CCR, 96 patients (48%) developed locoregional regrowths, and 33 patients (17%) developed distant metastases. R1 rate was 2% in both groups and postoperative 90-day mortality was 4% (active surveillance) versus 5% (standard surgery). Median DFS for active surveillance was 35 (95% CI 31 – 41) versus 49 months (95% CI 38 – NA) for standard surgery (HR 1.35, 95% CI 0.89 – 2.03, p = 0.15). At 30 months after nCRT, 43% of patients with active surveillance versus 34% with standard surgery developed distant metastases (OR 1.45, 95% CI 0.85 – 2.48, p = 0.18). HRQOL was statistically significantly better at six (p = 0.002) and nine months (p = 0.007) for active surveillance.
Conclusions
After a follow-up of two years, patients undergoing active surveillance had noninferior OS and improved short-term HRQOL compared to standard surgery. Postponed esophagectomy for locoregional regrowth was safe. Extended follow-up is required to assess long-term efficacy of active surveillance.
Clinical trial identification
NTR6803 8-11-2017.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This study was funded by the Dutch Cancer Society (KWF) and Netherlands Organisation for Health Research and Development (ZonMw).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
LBA74 - Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy in locally-advanced gastric and gastroesophageal junction cancer: The phase III KEYNOTE-585 study
Presenter: Kohei Shitara
Session: Proffered Paper session 1 - Gastrointestinal tumours, upper digestive
Resources:
Abstract
Slides
Webcast
LBA73 - Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
Presenter: Salah-Eddin Al-Batran
Session: Proffered Paper session 1 - Gastrointestinal tumours, upper digestive
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA74 and LBA73
Presenter: Elizabeth Smyth
Session: Proffered Paper session 1 - Gastrointestinal tumours, upper digestive
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session 1 - Gastrointestinal tumours, upper digestive
Resources:
Webcast
Invited Discussant LBA75
Presenter: Magnus Nilsson
Session: Proffered Paper session 1 - Gastrointestinal tumours, upper digestive
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session 1 - Gastrointestinal tumours, upper digestive
Resources:
Webcast
1511O - Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Survival results from the phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study
Presenter: Yelena Janjigian
Session: Proffered Paper session 1 - Gastrointestinal tumours, upper digestive
Resources:
Abstract
Slides
Webcast
Invited Discussant 1511O
Presenter: Florian Lordick
Session: Proffered Paper session 1 - Gastrointestinal tumours, upper digestive
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session 1 - Gastrointestinal tumours, upper digestive
Resources:
Webcast